Sakiris Spiro Kevin 4

What Happened

• Spiro K. Sakiris, Chief Financial Officer of Intelligent Bio Solutions, was granted two awards on March 18, 2026: 9,150 restricted shares and 21,350 restricted shares, for a total of 30,500 shares. Each grant shows an acquisition price of $0.00 (i.e., awarded shares, not purchased). The awards are subject to forfeiture until they vest.

Key Details

• Transaction date: March 18, 2026; Form 4 filed March 20, 2026 (timely within reporting window).
• Grant details:
  • 9,150 restricted shares (time-based vesting over 48 months).
  • 21,350 restricted shares (subject to combined performance-based and time-based vesting).
• Price: $0.00 per share (awarded shares, no cash exchanged).
• Shares owned after transaction: not reported in the provided excerpt of the Form 4.
• Footnotes of note:
  • All amounts are presented post-1-for-10 reverse stock split effected Dec 15, 2025.
  • The 2019 Long Term Incentive Plan governs these awards.
  • The securities are held by Anest Holdings Pty Ltd as trustee for the S&T Sakiris Superannuation Fund; Mr. Sakiris is a director of that trustee.

Context

• These are restricted stock awards (compensation grants), not open-market purchases or sales. Such awards are routine executive compensation and become valuable only if and when vesting conditions are met; they do not indicate an immediate purchase or sale. The performance- and time-based vesting means future retention of the shares depends on meeting specified targets and remaining employed through vesting periods.